Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405888 | 0.89 | KDM4E (0.61) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL404586 | 0.87 | KDM4E (0.61) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL401367 | 0.85 | KDM4E (0.71) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL404491 | 0.85 | PDE5A (0.67) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL405665 | 0.84 | PDE5A (0.66) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL400692 | 0.83 | PDE5A (0.68) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL401995 | 0.83 | PDE5A (0.67) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL400381 | 0.82 | KDM4E (0.61) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL402807 | 0.82 | PDE5A (0.69) | KDM4ERECQLPDE5APOLBLMNA | |
| SCHEMBL401473 | 0.82 | KDM4E (0.64) | KDM4ERECQLPDE5APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050739-B1 | QUINAZOLINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-8101624-B2 | Quinazoline derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-101557826-A | Therapeutic agent for urinary tract disease | ASKA PHARM CO LTD (JP) | 2009-10-14 | — | — | CN | disclosed |
| CN-101501007-A | Quinazoline derivative | ASKA PARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050739-A1 | QUINAZOLINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | KDM4E 4291/4885RECQL 878/4885PDE5A 14/4885 |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | PDE9A, PDE3A, PDE5A | KDM4E 2869/4885RECQL 100/4885PDE5A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.